An interventional study of Sequence: Clinical/Research and Sequence: Research/Clinical in Hypertension, sponsored by Institut de Recherches Cliniques de Montreal. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-11.
Sponsored by Institut de Recherches Cliniques de Montreal · Not applicable, Interventional, and Diagnostic
Among 286 studies in Hypertension with a site in Canada — 27 open to participants now, 38 under way, 7 of them phase 3. Hypertension · Canada.
Among the 286 studies in Hypertension with a site in Canada, this one is the 167th largest by enrollment of the 241 interventional ones, is one of 9 that started in 2017, is one of 118 with no phase, and was the 188th registered.
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's enrollment of 70 is below the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →27 of the 286 studies in Hypertension with a site in Canada are open now, in 12 countries. Each count lists the studies.
Of the 564 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →286 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 9 started in 2017.
Median enrollment 169 across the 241 interventional studies, 60 across the 45 observational. Of the 210 that completed or were terminated, 52 (25%) have results posted.
79 of 286 have an industry lead sponsor. The 10 most frequent:
Institut de Recherches Cliniques de Montreal is the lead sponsor of 61 studies on the registry; 11 are open to participants now.
Institut de Recherches Cliniques de Montreal has 3 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
12 of the studies in Hypertension with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT05543720University Health Network, TorontoEvaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
Among the 286 studies in Hypertension with a site in Canada, from their registry updates:
Automated office blood pressure (AOBP) devices are recommended for high blood pressure diagnosis. One of those devices is the Omron HEM-907 (Omron Healthcare). It is currently not known if blood pressure measurements performed with this device in a clinical setting are equivalent to those made in a research setting. Therefore, this randomized-controlled trial was designed. It aims to compare the blood pressure measurements performed in a clinical and a research setting. Seventy patients will be included and randomized to a clinical/research or research/clinical sequence.
Hypertension is a common condition, with an estimated prevalence around 20 percent in Canada. It is a major risk factor for cardiovascular disease. Recently, Hypertension Canada has updated its guidelines and recommend we should consider a 120 mm Hg systolic blood pressure target in high-risk patients aged 50 years or older. This recommendation derives mainly from the SPRINT trial. In this trial, blood pressure was measured with an automated oscillometric blood pressure (AOBP) device, the Omron HEM-907 (Omron Healthcare). However, it is not known if measurements performed with this device in a clinical setting are equivalent to those made in a research setting. Therefore, this randomized-controlled trial was designed. It aims to compare the blood pressure measurements of 70 patients in a clinical and a research setting. Patients will be randomized to a clinical/research or a research/clinical sequence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants assigned to this arm will have their blood pressure measured in a clinical setting first, and in a research setting second. The sequence randomization corresponds to the intervention. Visits will be at least a day apart but within a two-week period. During the clinical visit, they will have their blood pressure measured with the Omron HEM-907, an automated office blood pressure (AOBP) device. During the research setting, participants will be guided through a series of research-driven steps such as study questionnaires and completion of consent forms. They will have their blood pressure measured in both arms with a mercury sphygmomanometer, and then 3 measurements with a mercury sphygmomanometer. AOBP measurements (Omron HEM-907) will be performed at the end of the visit.
Other: Sequence: Clinical/Research
Participants assigned to this arm will go through the same measurements and procedures exception made of the research-first and clinical-second sequence. The intervention to which they are randomized corresponds to the sequence of the visits.
Other: Sequence: Research/Clinical
Participants will be assigned to a sequence of: research visit first/clinical visit second.
Participants will be assigned to a sequence of: clinical visit first/research visit second.
Mean automated office blood pressure systolic blood pressure estimates
Time frame: Up to 2 weeks
Mean automated office blood pressure diastolic blood pressure estimates.
Time frame: Up to 2 weeks
Individual unaveraged automated office systolic and diastolic blood pressure measurements (1, 2 and 3)
Time frame: Up to 2 weeks
Plan to share: Yes — according to specific scientifically pertinent demands
Ran from Nov 2017 to primary completion in Mar 2018, 4 months.
Of 1,403 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 4 months is below that.
Counting every sponsor, half of 1,498 studies reached it within 23 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut de Recherches Cliniques de Montreal